Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Nuvation Bio Earnings Call: Key Takeaways

Nuvation Bio reported strong Iptrosi growth despite a 15% market-wide decline in ROS1 TKI starts, while advancing its IDH1 mutant glioma program toward 2027 data readouts.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthUS Iptrosi $27.5M (18% growth); Collaboration/License $17.5M including $7.7M milestones/royalties.
Mgmt ConfidenceHigh confidence in Iptrosi's 50-month DOR benchmark and Safusidenib's differentiated profile.
Demand Visibility60% market share in first-line starts; 160 new patients this quarter.
Margin TrendsGross-to-net deductions stable at approximately 30%; Iptrosi now a self-sustaining program.
Op. LeverageIptrosi revenue run rate now covers its own launch-related operating expenses.
Vol vs PriceGrowth driven by 18% sequential increase in active patient base.
Segment GrowthChina and Japan launches exceeding expectations; US market leading in active patients.
New ClientsMajor community pathway reinforced Iptrosi as primary first and second-line choice.
Capex & Debt$663.4M cash balance; includes proceeds from December convertible debt offering.
RegulatoryFDA granted Fast Track designation for Safusidenib in IDH1 mutant glioma.
CommentaryEmphasized Iptrosi's lack of CNS warning vs competitors as key differentiator.
New LaunchesPlanning drug-drug conjugate (DDC) platform update and clinical entry by year-end.

Growth

Total revenue $45M; Iptrosi US net revenue $27.5M, up 18% sequentially.

Outlook

Anticipated $30M milestone from European approval in 1H 2027; Safusidenib data expected in 2027.

Risks

15% decline in total ROS1 TKI market starts; management pivoted to 'lumpiness' without specific Q4 guidance.

Source

The company's earnings call, NYSE: NUVB, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Nuvation Bio Inc.: key numbers

Share price
$3.84Close, Nov 16
Market cap
$1.36B
Shares outstanding
353.02MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Nuvation Bio Inc.

All →
4:18 PM ET 8-K
Financial Results

Nuvation Bio Financial Results

Nuvation Bio reported third quarter 2026 financial results, highlighted by $45.0 million in total revenue and $27.5 million in net product revenue for its ROS1 inhibitor IBTROZI. The company ended the quarter with $663.4 million in cash and marketable securities while achieving market leadership in new patient starts for ROS1+ NSCLC.

“Just over one year after launch, IBTROZI was established as the market leader in advanced ROS1+ NSCLC, for both new patient starts and active patients across all lines of therapy combined, based on IQVIA claims data.”

David Hung, M.D., Founder, President, and Chief Executive Officer

“Our rapid rise to market leadership reflects growing provider confidence in IBTROZI’s durability of more than four years in TKI-naïve patients and a generally favorable safety profile that helps patients stay on therapy.”

David Hung, M.D., Founder, President, and Chief Executive Officer
4:10 PM ET 10-Q
Financial Results ▶ Call

Nuvation Bio Q3 2026 Results: Net Loss of $41.9M, Loss Narrows

Nuvation Bio Inc. reported financial results for the third quarter of 2026, highlighting continued progress in its clinical oncology programs. The company maintained a robust cash position to support operations through 2028, while reporting a net loss driven by ongoing research and development expenses.

Key figure
Net loss $41.9M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.